Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
Launched by HOSPICES CIVILS DE LYON · May 21, 2024
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how copper is released in the urine of patients with Wilson's Disease, a condition where the body cannot properly get rid of copper, leading to its build-up in organs like the liver and brain. The study aims to determine the best time of day to measure urinary copper excretion, which can help doctors manage treatment more effectively. Currently, patients collect their urine over a full 24 hours, which can be challenging. By understanding when copper levels in urine are highest, it may be possible to make monitoring easier and more accurate.
To participate in this trial, patients must be between the ages of 6 and 70 and have a confirmed diagnosis of Wilson's Disease. They should be currently receiving treatment with specific medications (D-Penicillamine, Trientine, or Zinc) and be able to collect urine over a 24-hour period. However, people who have recently changed their treatment, have had a liver transplant, or have certain kidney issues cannot join the study. If eligible, participants can expect to help researchers learn more about how to improve care for Wilson's Disease by providing important information about their urinary copper levels at different times of the day.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ˃4).
- • Age ≥ 6 years and ≤70 years.
- • Patient able to perform 24h urine.
- • Current treatment with D-Pencillamine, Trientine or Zinc.
- • Non-opposition of patient and/or legal representatives for minor patients.
- Exclusion Criteria:
- • Patients who had a change in treatment within the last 6 months before the inclusion
- • Patients who have undergone liver transplantation
- • Patients with known chronic renal failure (GFR \< 30 ml/min)
- • Patients on long-term diuretic or corticosteroid therapy
- • Persons deprived of liberty by a judicial or administrative decision
- • Patient under judicial protection, unable to express consent
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bron, Rhone, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported